Medicare AdvantageBilling CodesMedium impact
Chimeric Antigen Receptor (CAR) T-cell Therapy - Medicare Advantage (Revised)
Humana·Oncology, Hematology·Medicare Advantage
Effective date
Sep 2, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has updated their CAR T-cell therapy policy with new CPT codes effective January 1, 2025, transitioning from temporary Category III codes to permanent CPT codes. The policy also adds a new HCPCS code for obecabtagene autoleucel effective April 1, 2025.
Action Required
By January 1, 2025: Billing team must update billing software to replace expiring Category III codes (0537T-0540T) with new permanent CPT codes (38225-38228) for CAR T-cell therapy procedures. By April 1, 2025: Add new HCPCS code C9301 for obecabtagene autoleucel to billing system. Update encounter forms and charge masters with new codes to ensure proper billing.